The role of MGuard stent in primary coronary angioplasty

F. Figini, A. Colombo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In a significant proportion of percutaneous coronary interventions (PCI) performed in the setting of acute myocardial infarction, despite apparently adequate restoration of blood flow in the target epicardial vessel, optimal myocardial reperfusion at tissue level is not achieved. This phenomenon, defined as no-reflow, has been consistently associated with negative outcomes; it involves many pathogenetic factors, including microvascular dysfunction and embolization of thrombus and plaque debris from the culprit lesion during PCI, particularly during stent deployment. Several strategies - either pharmacological or mechanical - have been developed in order to prevent or reduce the incidence of no-reflow, but this phenomenon still remains a major issue in primary coronary intervention. The MGuard stent is a relatively new device intended to ameliorate tissue reperfusion by reducing distal embolization: it consists of a balloon-expandable, bare metal stent platform, whose outer surface is covered by a mesh of polyethylene terephthalate (PET), so that after expansion the thrombus is entrapped between the stent struts and the vessel wall. This stent has been tested in lesions with a high embolic risk, as on vein grafts or in the setting of acute coronary syndromes. In this paper, we will review and discuss the data available about this device, with a particular focus on its use in primary PCI.

Original languageEnglish
Pages (from-to)29-38
Number of pages10
JournalMinerva Cardioangiologica
Volume62
Issue number1
Publication statusPublished - Feb 2014

Fingerprint

Angioplasty
Stents
Percutaneous Coronary Intervention
Thrombosis
No-Reflow Phenomenon
Equipment and Supplies
Myocardial Reperfusion
Polyethylene Terephthalates
Acute Coronary Syndrome
Reperfusion
Veins
Metals
Myocardial Infarction
Pharmacology
Transplants
Incidence

Keywords

  • Myocardial infarction
  • No-reflow phenomenon
  • Percutaneous coronary intervention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The role of MGuard stent in primary coronary angioplasty. / Figini, F.; Colombo, A.

In: Minerva Cardioangiologica, Vol. 62, No. 1, 02.2014, p. 29-38.

Research output: Contribution to journalArticle

Figini, F & Colombo, A 2014, 'The role of MGuard stent in primary coronary angioplasty', Minerva Cardioangiologica, vol. 62, no. 1, pp. 29-38.
Figini, F. ; Colombo, A. / The role of MGuard stent in primary coronary angioplasty. In: Minerva Cardioangiologica. 2014 ; Vol. 62, No. 1. pp. 29-38.
@article{883e1d6cbc6f4b4693693fc77ee9723f,
title = "The role of MGuard stent in primary coronary angioplasty",
abstract = "In a significant proportion of percutaneous coronary interventions (PCI) performed in the setting of acute myocardial infarction, despite apparently adequate restoration of blood flow in the target epicardial vessel, optimal myocardial reperfusion at tissue level is not achieved. This phenomenon, defined as no-reflow, has been consistently associated with negative outcomes; it involves many pathogenetic factors, including microvascular dysfunction and embolization of thrombus and plaque debris from the culprit lesion during PCI, particularly during stent deployment. Several strategies - either pharmacological or mechanical - have been developed in order to prevent or reduce the incidence of no-reflow, but this phenomenon still remains a major issue in primary coronary intervention. The MGuard stent is a relatively new device intended to ameliorate tissue reperfusion by reducing distal embolization: it consists of a balloon-expandable, bare metal stent platform, whose outer surface is covered by a mesh of polyethylene terephthalate (PET), so that after expansion the thrombus is entrapped between the stent struts and the vessel wall. This stent has been tested in lesions with a high embolic risk, as on vein grafts or in the setting of acute coronary syndromes. In this paper, we will review and discuss the data available about this device, with a particular focus on its use in primary PCI.",
keywords = "Myocardial infarction, No-reflow phenomenon, Percutaneous coronary intervention",
author = "F. Figini and A. Colombo",
year = "2014",
month = "2",
language = "English",
volume = "62",
pages = "29--38",
journal = "Minerva Cardioangiologica",
issn = "0026-4725",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - The role of MGuard stent in primary coronary angioplasty

AU - Figini, F.

AU - Colombo, A.

PY - 2014/2

Y1 - 2014/2

N2 - In a significant proportion of percutaneous coronary interventions (PCI) performed in the setting of acute myocardial infarction, despite apparently adequate restoration of blood flow in the target epicardial vessel, optimal myocardial reperfusion at tissue level is not achieved. This phenomenon, defined as no-reflow, has been consistently associated with negative outcomes; it involves many pathogenetic factors, including microvascular dysfunction and embolization of thrombus and plaque debris from the culprit lesion during PCI, particularly during stent deployment. Several strategies - either pharmacological or mechanical - have been developed in order to prevent or reduce the incidence of no-reflow, but this phenomenon still remains a major issue in primary coronary intervention. The MGuard stent is a relatively new device intended to ameliorate tissue reperfusion by reducing distal embolization: it consists of a balloon-expandable, bare metal stent platform, whose outer surface is covered by a mesh of polyethylene terephthalate (PET), so that after expansion the thrombus is entrapped between the stent struts and the vessel wall. This stent has been tested in lesions with a high embolic risk, as on vein grafts or in the setting of acute coronary syndromes. In this paper, we will review and discuss the data available about this device, with a particular focus on its use in primary PCI.

AB - In a significant proportion of percutaneous coronary interventions (PCI) performed in the setting of acute myocardial infarction, despite apparently adequate restoration of blood flow in the target epicardial vessel, optimal myocardial reperfusion at tissue level is not achieved. This phenomenon, defined as no-reflow, has been consistently associated with negative outcomes; it involves many pathogenetic factors, including microvascular dysfunction and embolization of thrombus and plaque debris from the culprit lesion during PCI, particularly during stent deployment. Several strategies - either pharmacological or mechanical - have been developed in order to prevent or reduce the incidence of no-reflow, but this phenomenon still remains a major issue in primary coronary intervention. The MGuard stent is a relatively new device intended to ameliorate tissue reperfusion by reducing distal embolization: it consists of a balloon-expandable, bare metal stent platform, whose outer surface is covered by a mesh of polyethylene terephthalate (PET), so that after expansion the thrombus is entrapped between the stent struts and the vessel wall. This stent has been tested in lesions with a high embolic risk, as on vein grafts or in the setting of acute coronary syndromes. In this paper, we will review and discuss the data available about this device, with a particular focus on its use in primary PCI.

KW - Myocardial infarction

KW - No-reflow phenomenon

KW - Percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=84900375019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900375019&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 29

EP - 38

JO - Minerva Cardioangiologica

JF - Minerva Cardioangiologica

SN - 0026-4725

IS - 1

ER -